First Capital Advisors Group, Llc. Gilead Sciences, Inc. Transaction History
First Capital Advisors Group, Llc.
- $188 Million
- Q2 2023
A detailed history of First Capital Advisors Group, Llc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, First Capital Advisors Group, Llc. holds 6,947 shares of GILD stock, worth $641,972. This represents 0.29% of its overall portfolio holdings.
Number of Shares
6,947
Previous 7,067
1.7%
Holding current value
$641,972
Previous $586,000
8.7%
% of portfolio
0.29%
Previous 0.38%
Shares
12 transactions
Others Institutions Holding GILD
# of Institutions
1,927Shares Held
994MCall Options Held
10.5MPut Options Held
9.75M-
Black Rock Inc. New York, NY121MShares$11.1 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$10.7 Billion0.18% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$7.07 Billion1.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.8MShares$5.71 Billion1.12% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.56 Billion0.21% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $116B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...